Type I IFNs can exert their potent antitumor effects by enhancing CD8+ T cell priming and infiltration, as well as inducing cancer cell death through IFN–IFN-α/β receptor signaling (Zitvogel et al., 2015). The gene discussed is CD8A; the disease is cancer.